Bright Minds Biosciences Income Statement

Financials in millions CAD. Fiscal year is October - September.

Millions CAD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019
Period Ending	Dec '24 Dec 31, 2024	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	Sep '20 Sep 30, 2020	2019
Selling, General & Admin	1.57	1.44	2.2	2.55	2.31	0.12	Upgrade
Research & Development	1	1.18	5	12.18	6.31	0.35	Upgrade
Operating Expenses	2.57	2.62	7.2	14.73	8.62	0.47	Upgrade
Operating Income	-2.57	-2.62	-7.2	-14.73	-8.62	-0.47	Upgrade
Interest Expense	-0.01	-0.01	-	-	-	-	Upgrade
Interest & Investment Income	0.03	0.03	-	-	-	-	Upgrade
Currency Exchange Gain (Loss)	1.65	-0.01	0.01	0.01	0.15	-	Upgrade
Other Non Operating Income (Expenses)	-0.16	-0.2	-0.19	-0.24	-0.18	-0.01	Upgrade
EBT Excluding Unusual Items	-1.07	-2.8	-7.37	-14.96	-8.65	-0.48	Upgrade
Asset Writedown	-	-	-	-0	-	-	Upgrade
Pretax Income	-1.07	-2.8	-7.37	-14.96	-8.65	-0.48	Upgrade
Net Income	-1.07	-2.8	-7.37	-14.96	-8.65	-0.48	Upgrade
Net Income to Common	-1.07	-2.8	-7.37	-14.96	-8.65	-0.48	Upgrade
Shares Outstanding (Basic)	5	4	4	2	2	1	Upgrade
Shares Outstanding (Diluted)	5	4	4	2	2	1	Upgrade
Shares Change (YoY)	29.26%	15.87%	50.58%	37.64%	148.42%	74.24%	Upgrade
EPS (Basic)	-0.22	-0.65	-1.98	-6.06	-4.82	-0.66	Upgrade
EPS (Diluted)	-0.22	-0.65	-1.98	-6.06	-4.82	-0.66	Upgrade
EBIT	-2.57	-2.62	-7.2	-14.73	-8.62	-0.47	Upgrade

Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q